Seattle Genetics (SGEN)

74.64 +0.43 (0.58%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (10/25/18 *Est.)
- M&A (3/31/18 *Est)

Latest Headlines

Form 4 SEATTLE GENETICS INC For: Aug 09 Filed by: SIEGALL CLAY B August 13, 2018 4:48 PM - SEC Filing Form CT ORDER SEATTLE GENETICS INC August 7, 2018 9:58 AM - SEC Filing Form 4 SEATTLE GENETICS INC For: Jul 31 Filed by: LIPPMAN MARC E August 2, 2018 8:01 PM - SEC Filing Seattle Genetics (SGEN) PT Raised to $79 at Needham & Company July 27, 2018 12:22 PM - StreetInsider Seattle Genetics (SGEN) PT Raised to $64 at Cowen July 27, 2018 11:29 AM - StreetInsider Seattle Genetics (SGEN) PT Raised to $81 at SunTrust Robinson Humphrey July 27, 2018 8:05 AM - StreetInsider Seattle Genetics (SGEN) PT Raised to $80 at Barclays July 27, 2018 4:45 AM - StreetInsider Form 8-K SEATTLE GENETICS INC For: Jul 26 July 26, 2018 5:28 PM - SEC Filing Form 424B7 SEATTLE GENETICS INC July 26, 2018 5:25 PM - SEC Filing Form S-8 SEATTLE GENETICS INC July 26, 2018 5:20 PM - SEC Filing Form 10-Q SEATTLE GENETICS INC For: Jun 30 July 26, 2018 5:14 PM - SEC Filing Form 8-K SEATTLE GENETICS INC For: Jul 26 July 26, 2018 4:08 PM - SEC Filing Seattle Genetics (SGEN) Reports Q2 EPS of $0.47, Revenues Beat; Offers FY18 Outlook July 26, 2018 4:05 PM - StreetInsider Seattle Genetics Reports Second Quarter 2018 Financial Results July 26, 2018 4:02 PM - BizWire Seattle Genetics (SGEN) Lower Following Update on Brentuximab Study July 17, 2018 9:56 AM - StreetInsider Seattle Genetics (SGEN) Reports First Patient Dosed in Phase 2 innovaTV 207 Trial Evaluating Tisotumab Vedotin in Multiple Solid Tumors July 12, 2018 8:01 AM - StreetInsider Seattle Genetics Announces First Patient Dosed in Phase 2 innovaTV 207 Trial Evaluating Tisotumab Vedotin in Multiple Solid Tumors July 12, 2018 8:00 AM - BizWire Form 4 SEATTLE GENETICS INC For: Jul 09 Filed by: SIEGALL CLAY B July 11, 2018 8:29 PM - SEC Filing Seattle Genetics (SGEN) Reports Publication of Results from Two Tucatinib Phase 1b Clinical Trials in HER2-Positive Metastatic Breast Cancer July 11, 2018 8:02 AM - StreetInsider Seattle Genetics Announces Publication of Results from Two Tucatinib Phase 1b Clinical Trials in HER2-Positive Metastatic Breast Cancer July 11, 2018 8:00 AM - BizWire Seattle Genetics (SGEN), Astellas Announce Progress in Enfortumab Vedotin Urothelial Cancer Clinical Development Program July 9, 2018 8:03 AM - StreetInsider Seattle Genetics and Astellas Announce Progress in Enfortumab Vedotin Urothelial Cancer Clinical Development Program July 9, 2018 8:00 AM - PR NewsWire Seattle Genetics and Astellas Announce Progress in Enfortumab Vedotin Urothelial Cancer Clinical Development Program July 9, 2018 8:00 AM - BizWire Seattle Genetics (SGEN) Adcetris On-going Launch in 1L cHL is Positive Says SunTrust. July 2, 2018 11:58 AM - StreetInsider Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter Financial Results on July 26, 2018 June 28, 2018 8:00 AM - BizWire BioClin Therapeutics Appoints Scott Myers as Chairman to its Board of Directors June 26, 2018 8:00 AM - BizWire Form 4 SEATTLE GENETICS INC For: Jun 15 Filed by: DANSEY ROGER D June 19, 2018 7:58 PM - SEC Filing Form 4 SEATTLE GENETICS INC For: Jun 12 Filed by: Cline Darren S June 14, 2018 6:32 PM - SEC Filing Seattle Genetics (SGEN) Reports First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin June 13, 2018 8:04 AM - StreetInsider Seattle Genetics Announces First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin for Women with Recurrent or Metastatic Cervical Cancer June 13, 2018 8:00 AM - BizWire Form 4 SEATTLE GENETICS INC For: Jun 08 Filed by: SIEGALL CLAY B June 12, 2018 7:35 PM - SEC Filing SunTrust Robinson Humphrey Upgrades Seattle Genetics (SGEN) to Buy; Improving Prospects For Adcetris In 1L HL June 11, 2018 6:34 AM - StreetInsider Seattle Genetics to Present at the Goldman Sachs 39th Annual Global Healthcare Conference June 6, 2018 8:00 AM - BizWire Form 4 SEATTLE GENETICS INC For: May 31 Filed by: HIMES VAUGHN B June 4, 2018 7:12 PM - SEC Filing Seattle Genetics (SGEN) Highlights Additional Analyses from Phase 3 ECHELON-1 Clinical Trial of ADCETRIS in Newly Diagnosed Advanced HL at ASCO June 4, 2018 9:09 AM - StreetInsider Seattle Genetics Highlights Additional Analyses from Phase 3 ECHELON-1 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma at 2018 ASCO Annual Meeting June 4, 2018 9:00 AM - BizWire Seattle Genetics (SGEN) & Astellas Update Phase 1 Data of Investigational Antibody-Drug Conjugate Enfortumab Vedotin June 4, 2018 6:37 AM - StreetInsider Astellas and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy June 3, 2018 9:00 AM - PR NewsWire Seattle Genetics and Astellas Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy June 3, 2018 9:00 AM - BizWire Form 3 SEATTLE GENETICS INC For: May 21 Filed by: DANSEY ROGER D May 31, 2018 7:38 PM - SEC Filing Form 4 SEATTLE GENETICS INC For: May 18 Filed by: AKKARAJU SRINIVAS May 22, 2018 8:17 PM - SEC Filing Form 4 SEATTLE GENETICS INC For: May 18 Filed by: WELCH DANIEL G May 22, 2018 8:14 PM - SEC Filing Form 4 SEATTLE GENETICS INC For: May 18 Filed by: Simonian Nancy A May 22, 2018 8:11 PM - SEC Filing Form 4 SEATTLE GENETICS INC For: May 18 Filed by: Orwin John A May 22, 2018 8:10 PM - SEC Filing Form 4 SEATTLE GENETICS INC For: May 18 Filed by: LIPPMAN MARC E May 22, 2018 8:08 PM - SEC Filing Form 4 SEATTLE GENETICS INC For: May 18 Filed by: GRYSKA DAVID W May 22, 2018 8:07 PM - SEC Filing Form 8-K/A SEATTLE GENETICS INC For: Mar 09 May 21, 2018 4:37 PM - SEC Filing Full Article List